Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Seniors face crushing drug costs as Congress stalls on capping Medicare out-of-pockets

Sharon Clark is able to get her life-sustaining cancer drug, Pomalyst — priced at more than $18,000 for a 28-day supply — only because of the generosity of patient assistance foundations.

4 Jan 2021

New cell therapy can boost immunotherapy against breast cancer

Boosting immune system T cells to effectively attack solid tumors, such as breast cancers, can be done by adding a small molecule to a treatment procedure called chimeric antigen receptor-T (CAR-T) cell therapy, according to a study by researchers at the UNC Lineberger Comprehensive Cancer Center.

4 Jan 2021

Cancer survivors have greater risk of developing and dying from subsequent primary cancers

A new American Cancer Society study finds that adult-onset cancer survivors run a greater risk of developing and dying from subsequent primary cancers (SPCs) than the general population.

22 Dec 2020

Moffitt study may lead to potential treatment options for cutaneous T cell lymphoma

Cutaneous T cell lymphomas (CTCLs) are a group of non-Hodgkin lymphomas that develop from T cells and mainly impact the skin with painful lesions.

21 Dec 2020

COVID-19 pandemic highlights the risk of using systemic corticosteroids

Healthcare workers in tropical and sub-tropical settings where strongyloidiasis is prevalent or caring for patients who have travelled to such areas, need to maintain a high level of awareness about the use of corticosteroids, including when this class of anti-inflammatories is given to patients suspected of infection with SARS-CoV-2.

17 Dec 2020

Regulating fas protein may be a route to prevent cancer relapse after immunotherapy

Mount Sinai researchers have solved one of the enduring mysteries of cancer immunotherapy: Why does it completely eliminate tumors in many patients, even when not all the cells in those tumors have the molecular target that the therapy is aimed at?

17 Dec 2020

Scientists demonstrate a promising strategy for treating lymphomas

Scientists at Scripps Research have demonstrated a promising new strategy for treating lymphomas, a group of cancers that begin in infection-fighting cells of the immune system called lymphocytes.

16 Dec 2020

New class of targeted cancer drugs may prove effective in treating common types of leukemia

A new study by researchers in Cleveland Clinic's Taussig Cancer Institute and Lerner Research Institute describes a novel class of targeted cancer drugs that may prove effective in treating certain common types of leukemia.

15 Dec 2020

Study shows how STAT5 optimizes function of CD4+ T cells to drive antitumor immunity

Cancer immunotherapy using "designer" immune cells has revolutionized cancer treatment in recent years. In this type of therapy, T cells, a type of white blood cell, are collected from a patient's blood and subjected to genetic engineering to produce T cells carrying a synthetic molecule termed chimeric antigen receptor (CAR) that is designed to enable T cells to recognize and destroy cancer cells.

14 Dec 2020

68Ga-pentixafor PET imaging is an effective diagnostic tool for CNS B-cell lymphoma

Positron emission tomography (PET) imaging with 68Ga-pentixafor is an effective diagnostic tool for central nervous system (CNS) B-cell lymphoma, according to a proof-of-concept study published in the December issue of The Journal of Nuclear Medicine.

10 Dec 2020

Study reveals low detection of SARS-CoV-2 on environmental surfaces across oncology settings

Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility.

7 Dec 2020

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Roswell Park Comprehensive Cancer Center's Francisco J. Hernandez-Ilizaliturri, MD, along with a team of researchers from other institutions, has been investigating a novel therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

7 Dec 2020

Researchers analyze outcomes in patients with primary central nervous system lymphoma

Primary central nervous system lymphoma (PCNSL) is a type of cancer that develops in the brain and or spinal cord.

7 Dec 2020

Study finds CAR T cell therapy as effective as first-line treatment for high-risk large B-cell lymphoma

A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments.

7 Dec 2020

Testing for tumor DNA can help predict risk of relapse after transplant in DLBCL patients

Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse.

7 Dec 2020

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.

7 Dec 2020

Study identifies multiple important genomic differences in BCL malignancies using genomic ancestry

B-cell lymphoma and leukemias (BCL) are a diverse set of malignancies. While the genomic landscape of many BCL subtypes has been described, genomic ancestry has rarely been explored.

6 Dec 2020

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial.

6 Dec 2020

Cancer cells exhibit metabolic changes that make them vulnerable to ferroptosis

If there is a silver lining in cancer's chaotic biology, it's that the same traits that give cancer cells a growth advantage often present opportunities for sabotaging them.

2 Dec 2020

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.

1 Dec 2020

Lymphoma News and Research

Further Reading

Seniors face crushing drug costs as Congress stalls on capping Medicare out-of-pockets

New cell therapy can boost immunotherapy against breast cancer

Cancer survivors have greater risk of developing and dying from subsequent primary cancers

Moffitt study may lead to potential treatment options for cutaneous T cell lymphoma

COVID-19 pandemic highlights the risk of using systemic corticosteroids

Regulating fas protein may be a route to prevent cancer relapse after immunotherapy

Scientists demonstrate a promising strategy for treating lymphomas

New class of targeted cancer drugs may prove effective in treating common types of leukemia

Study shows how STAT5 optimizes function of CD4+ T cells to drive antitumor immunity

68Ga-pentixafor PET imaging is an effective diagnostic tool for CNS B-cell lymphoma

Study reveals low detection of SARS-CoV-2 on environmental surfaces across oncology settings

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Researchers analyze outcomes in patients with primary central nervous system lymphoma

Study finds CAR T cell therapy as effective as first-line treatment for high-risk large B-cell lymphoma

Testing for tumor DNA can help predict risk of relapse after transplant in DLBCL patients

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Study identifies multiple important genomic differences in BCL malignancies using genomic ancestry

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

Cancer cells exhibit metabolic changes that make them vulnerable to ferroptosis

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News